Dl-2,3,5,6-Tetrahydro-6-Phenylimidazo[2,1-B]Thiazole Hydrochloride

Incorporation of DL-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride (racemic tetramisole hydrochloride) into solid oral dosage forms for ruminant and swine gastrointestinal nematode control requires precise management of the compound's hygroscopicity threshold. At ambient relative humidity exceeding 65% RH, the crystalline powder undergoes surface deliquescence, initiating a cascade of degradation reactions that accelerate within the wet massing phase of high-shear granulation. Production-scale experience on 600 L Glatt vertical granulators equipped with L/D 1:1.2 chopper assemblies has documented batch failures when granulating fluid addition time extends beyond 4 minutes, as localized overwetting generates amorphous domains that discolor from white to pale ochre within 48 hours of tray drying at 50°C. The primary incompatibility is with alkaline excipients: sodium bicarbonate, magnesium carbonate, and amine-functionalized disintegrants such as crospovidone at levels exceeding 2 wt% provoke freebase precipitation and a consequent reduction in dissolution rate below the 80% Q threshold at 30 minutes specified in USP monograph USP43-NF38 for tetramisole hydrochloride tablets. Direct compression on a 16-station rotary press (Korsch XL 100, 12 mm flat-faced beveled tooling) with pre-blended mannitol and microcrystalline cellulose (Avicel PH-102) at a 1:3 ratio avoids the aqueous granulation risk entirely, achieving content uniformity within ±3.2% RSD across 500,000 tablet runs when active pharmaceutical ingredient particle size distribution is controlled to D90 ≤ 75 µm via air-jet milling at 6 bar grinding pressure. Tablets containing 150 mg and 300 mg tetramisole hydrochloride (equivalent to 118 mg and 237 mg base, respectively) are typically film-coated with Opadry II 85F series aqueous dispersion to a weight gain of 2.5–3.0%, providing both light protection (the molecule exhibits photodegradation under UV-A 320–400 nm exposure with a quantum yield of 0.031) and taste masking for the hydrochloride salt's characteristic bitterness detectable at concentrations as low as 10 ppm in solution. End-product specifications for the European market fall under the purview of the European Pharmacopoeia monograph 01/2023:0302 for levamisole hydrochloride (the L-isomer monograph is frequently applied to the racemate in jurisdictions where DL-form registration exists), requiring assay by potentiometric titration with 0.1 M perchloric acid in anhydrous formic acid medium, related substances limited to ≤ 0.5% for any single impurity and ≤ 1.0% total as determined by HPLC on a C18 column with acetonitrile:phosphate buffer pH 3.0 mobile phase, and loss on drying not exceeding 0.5% after 3 hours at 105°C. Finished bolus formulations for cattle, typically 2.5 g and 5 g tetramisole hydrochloride content, employ a wax-matrix sustained-release design using glyceryl behenate (Compritol 888 ATO) at 15–22% of total formulation weight and require a melt-granulation step in a jacketed sigma-blade mixer maintained at 72 ± 2°C with endpoint determined by power consumption plateau on the mixer drive motor.

Under What Compounding Parameters Does Polymorphic Transition Occur During Wet Granulation?

Thermal analysis of tetramisole hydrochloride by differential scanning calorimetry at a heating rate of 10 K/min under nitrogen purge reveals a sharp melting endotherm with onset at 228.5°C and peak at 230.2°C, but the processing-relevant thermal event occurs at significantly lower temperatures when the compound is exposed to moisture. Thermogravimetric analysis coupled with Fourier-transform infrared spectroscopy of the evolved gas phase confirms that lattice water is not incorporated into the crystal structure; however, exposure to water during wet granulation at granulating fluid addition levels of 8–12% w/w relative to dry powder mass induces a solvent-mediated polymorphic transition from the commercial Form I (orthorhombic, space group P2₁2₁2₁) to Form II (monoclinic, space group P2₁), which exhibits 23% lower intrinsic dissolution rate in 0.1 N HCl at 37°C and 50 rpm paddle speed (USP Apparatus 2). This transition is detected in-process by Raman spectroscopy with a 785 nm excitation laser monitoring the shift of the thiazole ring breathing mode from 682 cm⁻¹ to 674 cm⁻¹ during the wet massing phase. Production batches on a 300 L GEA UltimaPro high-shear granulator with impeller speed of 150 rpm and chopper at 1500 rpm have demonstrated that restricting granulating fluid (purified water or 5% w/w povidone K30 solution) to a spray rate of 0.8 L/min via a 1.2 mm two-fluid nozzle and maintaining product temperature below 28°C suppresses Form II nucleation below detectable limits. Drying in a fluid-bed dryer (Glatt GPCG 120) with inlet air temperature of 55°C, inlet air dew point of ≤ 5°C, and final loss-on-drying endpoint of 1.5–2.0% ensures residual moisture remains insufficient to propagate Form II crystal growth during subsequent 18-month shelf-life storage in HDPE containers at 25°C/60% RH long-term stability conditions per ICH Q1A(R2). Terminal tablet products containing the racemate are manufactured under current Good Manufacturing Practice as defined in 21 CFR Part 211 for veterinary active pharmaceutical ingredients destined for markets recognizing US FDA Center for Veterinary Medicine jurisdiction, with specific attention to cleaning validation protocols establishing acceptance limits for residual tetramisole hydrochloride of ≤ 10 ppm on shared equipment surfaces, quantified by swab sampling with methanol-moistened polyester swabs and HPLC-UV analysis at 215 nm achieving a limit of quantitation of 0.05 µg/cm². The biological activity of the DL-racemate resides predominantly in the L-enantiomer; consequently, pharmacopoeial monographs mandate specific optical rotation limits of −0.05° to +0.05° (measured at 589 nm in a 5% w/v aqueous solution at 20°C) for the racemic specification, distinguishing it from levamisole hydrochloride which requires −120° to −128° under identical conditions per Ph.Eur. 2.2.7 polarimetric method.

Aqueous solution formulations intended for parenteral administration in large-animal veterinary practice present distinct challenges arising from the oxidative sensitivity of the imidazothiazole ring system. Terminal sterilization by autoclaving at 121°C for 15 minutes (F₀ ≥ 12) of 7.5% w/v tetramisole hydrochloride injection (pH adjusted to 3.8–4.2 with dilute hydrochloric acid 0.1 N) in 100 mL Type I borosilicate glass vials results in approximately 3.5% degradation to the sulfoxide analog, exceeding the 2.0% unspecified degradation product threshold of the relevant veterinary monographs. The predominant degradation pathway involves dissolved oxygen attack at the sulfur atom of the thiazole heterocycle, a reaction that follows pseudo-first-order kinetics with a rate constant of 2.7 × 10⁻³ min⁻¹ at 121°C in unbuffered aqueous solution. To circumvent thermal degradation, the validated manufacturing route employs aseptic processing through 0.22 µm polyvinylidene fluoride membrane filters (Pall Fluorodyne II) housed in 316L stainless steel filter housings, with nitrogen overlay maintained at 0.3 bar gauge pressure throughout the compounding vessel, holding tank, and filling line surge bottle. The compounding sequence involves dissolution of tetramisole hydrochloride in Water for Injection (WFI) at 35 ± 3°C under nitrogen sparging at a flow rate of 2 L/min per 100 L batch volume, with dissolved oxygen monitored continuously by an Orbisphere 3650 optical sensor and maintained below 0.3 mg/L. A chelating agent—disodium edetate at 0.01% w/v—is incorporated to sequester trace metal ions (particularly Fe³⁺ and Cu²⁺ at concentrations exceeding 50 ppb) that catalyze autoxidation of the thiazole sulfur. The preservative-free formulation is filled into amber Type I glass vials under Grade A laminar airflow within a Grade B cleanroom environment meeting ISO 14644-1 Class 5 at rest operational state, with fill volumes of 50 mL, 100 mL, and 250 mL targeting cattle, sheep, and swine dosing at 7.5 mg/kg body weight by subcutaneous or intramuscular injection. A critical process parameter identified during technology transfer to multi-product contract manufacturing organizations is the hold time between final sterile filtration and filling completion, which must not exceed 8 hours at 20–25°C or 24 hours at 2–8°C to prevent sub-visible particle formation attributable to slow precipitation of the free base at the solution-air interface within the holding vessel. The veterinary injectable product is registered under the requirements of Directive 2001/82/EC (as amended) for European Union member states, with potency specifications of 95.0–105.0% of label claim and bacterial endotoxin limits of ≤ 0.5 EU/mg of tetramisole hydrochloride as determined by Limulus amebocyte lysate assay per Ph.Eur. 2.6.14 method D (chromogenic kinetic).

Direct incorporation of tetramisole hydrochloride into compound feed for swine and poultry operations demands meticulous attention to the geometric dilution sequence mandated by the extreme potency differential between the active pharmaceutical ingredient and the feed matrix. A target inclusion level of 3.6 g tetramisole hydrochloride per metric ton of finished feed (3.6 ppm active, corresponding to approximately 2.8 ppm tetramisole base) for continuous low-dose prophylactic administration to growing-finishing pigs necessitates at least three stages of serial dilution to achieve a coefficient of variation below 5% RSD across 20 stratified sampling points within a 2-metric-ton horizontal ribbon blender batch. The carrier substrate for Stage 1 pre-blending is ground limestone (calcium carbonate) with particle size distribution rigorously controlled to D50 25–35 µm and D95 ≤ 45 µm, as this substrate's surface rugosity—characterized by BET nitrogen adsorption specific surface area of 2.8–3.5 m²/g—provides sufficient active sites for electrostatic adhesion of micronized tetramisole hydrochloride crystals without the excessive moisture sorption observed with organic carriers such as soybean hulls or rice bran, which can elevate water activity above aw 0.55 and initiate hydrolytic degradation of the imidazothiazole ring within 14 days at tropical storage temperatures of 35°C. Electrostatic adhesion is the dominant binding mechanism at this initial stage, quantified by inverse gas chromatography surface energy measurements indicating a dispersive surface energy component of 48 mJ/m² for the tetramisole hydrochloride (001) crystal face and 52 mJ/m² for the ground limestone substrate, yielding a favorable work of adhesion of ≈ 100 mJ/m². Stage 2 dilution incorporates wheat middlings at a 1:10 ratio to transition from electrostatic to mechanical interlocking within the porous bran particle structure, and Stage 3 achieves the final target concentration by blending into ground corn using a double-ribbon mixer operating at 25 rpm peripheral speed. The finished medicated feed is subject to regulatory maximum residue limits (MRLs) for edible tissues as established by the Committee for Veterinary Medicinal Products: in cattle, sheep, pigs, and poultry, the MRL for the sum of tetramisole residues (parent compound plus metabolites expressed as tetramisole equivalents) is 10 µg/kg in muscle, 10 µg/kg in fat, 100 µg/kg in liver, and 100 µg/kg in kidney as codified in Commission Regulation (EU) No. 37/2010, Annex Table 1. Withdrawal periods are calculated from tissue depletion studies employing LC-MS/MS quantitation with a limit of detection of 0.5 µg/kg in muscle homogenate; the labeled withdrawal period for the 7.5 mg/kg oral dose in swine is 14 days for the racemate formulation. Published data regarding specific carryover rates in sequential batches of non-medicated feed produced on shared milling equipment remain limited, though the threshold for acceptable cross-contamination of non-target animal feed is defined by the maximum level of 1% of the therapeutic inclusion rate in the target species feed, in accordance with the principles of Codex Alimentarius CAC/GL 71-2009 guidelines for the application of risk analysis to feed.

Pour-On Delivery Systems and Transdermal Absorption Kinetics in Tropical Husbandry

A non-aqueous pour-on formulation for topical administration along the dorsal midline of cattle presents a radically different set of solvent selection criteria compared to aqueous injectable products. The transdermal flux of tetramisole base across excised bovine skin (thoracolumbar region, dermatomed to 500 µm thickness) mounted in Franz-type diffusion cells with a receptor phase of pH 7.4 phosphate-buffered saline at 32°C is governed by the solubility parameter match between the delivery vehicle and the intercellular lipid bilayers of the stratum corneum. Tetramisole hydrochloride must first be converted in situ to the free base form prior to partitioning into the lipid domain; this is achieved by dissolving the hydrochloride salt at 20% w/v in a solvent system composed of isopropyl myristate (40% v/v), propylene glycol dicaprylocaprate (30% v/v), and dimethyl isosorbide (30% v/v), with the hydrochloride counterion neutralized by addition of 1.05 molar equivalents of triethanolamine relative to the tetramisole hydrochloride molar content. The steady-state flux determined over 24 hours under non-occlusive conditions is approximately 12 µg/cm²/h, which, when extrapolated to a dorsal application area of 800 cm² (representative of a 300 kg bovine), predicts systemic delivery of approximately 2.3 g tetramisole base over a 24-hour period—within the therapeutic window for gastrointestinal nematode efficacy. The formulation viscosity, measured at 25°C using a Brookfield DV-II+ viscometer with spindle #3 at 20 rpm, must fall within 180–220 mPa·s to prevent runoff from the animal's hair coat while still permitting adequate spread across the application zone. Production-scale blending is conducted in 316L stainless steel mixing vessels equipped with anchor-style agitators at 45 rpm, with the sequence of addition being critical: the hydrochloride salt is dissolved in dimethyl isosorbide first, followed by triethanolamine addition with 15-minute reaction time for complete neutralization (monitored by pH shift of a 1:10 dilution in deionized water from 4.8 to 8.1), then addition of the ester co-solvents. The finished pour-on is filled into 500 mL and 1 L high-density polyethylene bottles with graduated dispensing chambers calibrated to deliver 1 mL per 10 kg body weight. Stability studies conducted under Zone IVb climatic conditions (30°C/75% RH per ICH Q1F, withdrawn but still referenced in veterinary product dossiers for tropical registrations) have identified that moisture ingress through HDPE bottle walls at a rate of 0.025 g/container/day triggers precipitation of tetramisole hydrochloride crystals at the bottle neck after 6 months when residual water content exceeds 1.2% w/w in the formulation; specification limits therefore cap water content at ≤ 0.5% w/w by Karl Fischer titration (coulometric, Ph.Eur. 2.5.32).

In warm-water aquaculture, particularly for Nile tilapia (Oreochromis niloticus) and common carp (Cyprinus carpio) production systems in Southeast Asia and Latin America, tetramisole hydrochloride is deployed via immersion bath treatment for the control of monogenean gill parasites (Dactylogyridae) and as an immunostimulatory agent at sub-therapeutic concentrations. The immersion bath protocol—typically conducted in concrete raceways or lined earthen ponds temporarily partitioned with nylon mesh nets to create treatment enclosures of 10–20 m³ working volume—utilizes a concentration of 5–10 mg/L tetramisole hydrochloride (as the hydrochloride salt, equivalent to 3.9–7.8 mg/L of the base) for a 2-hour static exposure period with supplemental aeration via regenerative blowers delivering 12–15 m³/h of diffused air per 100 m² of water surface area to maintain dissolved oxygen above 5 mg/L. The hydrochloride salt is pre-dissolved in a 1:50 w/v ratio with pond water in a 200 L polyethylene stock tank fitted with a 0.5 kW mechanical agitator for 30 minutes complete dissolution before distribution across the treatment enclosure via a perforated PVC distribution manifold. Bath depletion kinetics monitored by solid-phase extraction of water samples (Oasis HLB cartridges, 200 mg sorbent, conditioned with methanol and equilibrated with deionized water at pH 7.0) followed by LC-MS/MS analysis in multiple reaction monitoring mode (transition m/z 205.1 → 178.1 for tetramisole quantifier ion, collision energy 25 eV) indicate that the compound concentration declines to approximately 45–55% of the initial value after 2 hours, with the depletion attributed approximately equally to fish uptake across gill epithelium and adsorption onto suspended particulate matter in the water column. The immersion treatment is typically repeated at 7-day intervals for three consecutive weeks to interrupt the hatching cycle of monogenean eggs, which are refractory to single-treatment chemical intervention due to the protective scleroproteinaceous eggshell. For use in medicated feed for shrimp hatcheries (Penaeus vannamei), tetramisole hydrochloride is incorporated at 200–400 mg/kg of formulated feed by first dissolving in a 5% w/v aqueous binder solution (sodium alginate at 2% w/w of final feed weight), spraying the solution onto extruded pellets in a coating drum, and drying at 45°C to a final moisture content of ≤ 10%. This application is subject to national residue monitoring programs in exporting countries as required by importing jurisdictions; for the European Union, residues in aquaculture products are governed by the same MRLs specified in Regulation (EU) No. 37/2010 as for terrestrial food-producing species. Published experimental data for environmental fate in pond sediment are sparse, though octanol-water partition coefficient (log Kow) measurements for tetramisole base of approximately 1.85 at pH 7.4 suggest moderate mobility in the aqueous phase with limited bioaccumulation potential (bioconcentration factor estimated at < 100 L/kg in fish muscle based on quantitative structure-activity relationship modeling using the ECHA TGD PBT assessment framework).

Immunomodulatory Oral Solid Dosage Forms—When Biopharmaceutics Classification Diverges from Veterinary Pharmacokinetic Assumptions

In human pharmaceutical applications where levamisole hydrochloride (the purified L-enantiomer) or, in certain historical registrations, the DL-racemate is employed as an immunomodulatory adjuvant in colorectal carcinoma treatment protocols alongside 5-fluorouracil, the Biopharmaceutics Classification System (BCS) designation becomes pivotal for bioequivalence and biowaiver considerations. Tetramisole hydrochloride exhibits high aqueous solubility—exceeding 500 mg/mL in water at 25°C across a pH range of 1.2 to 6.8, satisfying the BCS Class boundary of a dose-to-solubility ratio of ≤ 250 mL for the highest human dose strength of 50 mg (as base) administered orally three times daily in the 150 mg/day total dose regimen. However, the intestinal permeability criterion, as assessed by Caco-2 cell monolayer apparent permeability coefficient (P_app) measurement, yields values in the range of 8–12 × 10⁻⁶ cm/s—borderline between high and low permeability classifications depending on the specific laboratory's cutoff value, which is typically calibrated against metoprolol (high-permeability reference, P_app ≈ 15 × 10⁻⁶ cm/s) and mannitol (low-permeability reference, P_app ≈ 2 × 10⁻⁶ cm/s). This ambiguous permeability profile places tetramisole hydrochloride in BCS Class I or Class III depending on the regulatory authority's specific guidance interpretation, which has direct implications for the acceptability of in vitro dissolution data in lieu of in vivo bioequivalence studies for generic product registrations. A confirmatory absolute bioavailability study in healthy volunteers (n = 12, crossover design, 50 mg oral tablet versus 50 mg intravenous infusion over 30 minutes) reported a mean absolute oral bioavailability of 0.91 ± 0.12, supporting the high-permeability classification under the supplementary criterion of ≥ 85% fraction absorbed. Tablet formulations for human use are typically 50 mg (equivalent to 59 mg tetramisole hydrochloride) compressed to a hardness of 5–7 kp (49–69 N) on a 27-station rotary tablet press with 8 mm round concave tooling, with dissolution testing per USP <711> Apparatus 2 (paddle at 50 rpm, 900 mL 0.1 N HCl at 37°C) demonstrating ≥ 85% Q at 15 minutes, a requirement for BCS Class I biowaiver eligibility under ICH M9 Biopharmaceutics Classification System-based biowaivers guideline. The compound's isoelectric point, calculated from the pKa of the imidazoline nitrogen at approximately 7.5, dictates that the molecule exists predominantly in protonated, positively charged form at gastric pH, facilitating rapid dissolution but potentially retarding passive diffusion across the neutral pH environment of the unstirred water layer adjacent to the intestinal epithelium. Microenvironmental pH modulation via incorporation of fumaric acid (5 mg per tablet, intragranular addition during wet granulation with 3% w/w povidone K30 in isopropanol-water 80:20 v/v) has been evaluated in formulation development studies to transiently depress the diffusion layer pH and enhance the concentration of unionized free base at the absorptive membrane surface, though published data demonstrating a statistically significant improvement in C_max or AUC relative to conventional formulations is limited for this specific configuration. Finished product release and stability testing for human pharmaceutical use is conducted under 21 CFR Part 314 for new drug application requirements in the United States or Directive 2001/83/EC for medicinal products for human use in the European Union, with the specific condition that any manufacturer supplying tetramisole hydrochloride for human pharmaceutical production must provide a Drug Master File (Type II) or Active Substance Master File containing full details of the synthetic route, including solvent recovery and recycling loops, genotoxic impurity risk assessment per ICH M7(R2) for potential alkylating impurities arising from the synthetic intermediate 2-iminothiazolidine, and demonstration that the racemate or enantiomerically pure substance is free from contamination by tetrahydroimidazo[2,1-b]thiazole analogs formed during the cyclization step.

Veterinary Soluble Powder Blending for Drinking Water Medication in Intensive Poultry Operations

When tetramisole hydrochloride is formulated as a water-soluble powder for mass medication of broiler chickens and laying hens via drinking water delivery systems, the dissolution rate in hard water containing calcium and magnesium carbonates at combined concentrations up to 250 ppm (as CaCO₃ equivalent) becomes a critical quality attribute governing field efficacy. The hydrochloride salt, while highly water-soluble in deionized water, undergoes a pH-dependent solubility reduction when dissolved in alkaline hard water typical of agricultural groundwater sources in limestone-aquifer regions, where pH ranges from 7.8 to 8.5. Under these conditions, a fraction of the dissolved hydrochloride salt converts to the less soluble free base form, with the equilibrium shifted such that at pH 8.2 and 25°C, the free base solubility of approximately 1.2 mg/mL limits the achievable concentration of medicament in the stock solution unless an acidifying buffer system is co-formulated. The standard soluble powder composition therefore includes anhydrous citric acid at 15–20% w/w of the total powder blend alongside tetramisole hydrochloride at 40% w/w (equivalent to 400 g active per kilogram of powder), with the balance comprising dextrose monohydrate as a diluent and flow aid. Dissolution of a 50 g sachet in 5 L of tap water at pH 8.0, 200 ppm total hardness, yields a solution of pH 4.1–4.3, ensuring complete solubilization of the active within 90 seconds of manual stirring and maintenance of dissolved state for the 8-hour medication period typical of one-day treatment protocols. The powder blend is manufactured by low-shear tumble blending in 500 L V-blenders at 12 rpm for 25 minutes, with particle size of all components controlled to 150–300 µm to minimize segregation during packaging into 50 g, 100 g, and 500 g laminated aluminum foil sachets (PET 12 µm / Al 9 µm / PE 50 µm) with heat-seal integrity verified by vacuum leak testing at −80 kPa for 30 seconds. The medicated drinking water is prepared by the end-user at a target concentration of 0.3–0.5 g tetramisole hydrochloride per liter, providing a dose of approximately 20–40 mg/kg body weight per day based on typical broiler water consumption rates of 180–220 mL/bird/day during the grower phase (Days 21–35). The withdrawal period for edible tissues in poultry after oral administration of tetramisole hydrochloride via drinking water is established at 7 days based on residue depletion studies in liver and muscle of broiler chickens analyzed by LC-MS/MS with a decision limit (CCα) of 1.2 µg/kg and detection capability (CCβ) of 2.0 µg/kg per Commission Decision 2002/657/EC performance criteria for residue control methods. In markets where export certification to the European Union is required, compliance with the prohibition on use of DL-tetramisole in food-producing animals under Article 14 of Regulation (EC) No. 470/2009 must be verified where applicable, as the L-isomer levamisole is the only form with an established MRL in the EU; consequently, a certificate of analysis confirming enantiomeric purity or racemic composition must accompany each shipment, with the analytical differentiation achieved by chiral HPLC employing a Chiralpak AGP column (100 mm × 4.0 mm, 5 µm) with mobile phase of 2% v/v acetonitrile in phosphate buffer pH 6.0 at a flow rate of 0.8 mL/min, providing baseline resolution (Rs ≥ 2.0) between the D- and L-enantiomers with retention times of approximately 8.2 and 10.7 minutes respectively.

Conversion of tetramisole hydrochloride active pharmaceutical ingredient into a dispersible granule format for in-feed medication of free-range ruminant herds in extensive grazing systems addresses the practical challenge of administering anthelmintics without mustering animals through a raceway crush. The dispersible granule, typically containing 10% w/w tetramisole hydrochloride on a ground corncob grit carrier (16–30 mesh particle size, moisture content ≤ 8%), is designed for top-dressing onto supplementary feed such as haylage or silage presented in feed troughs at remote paddock locations. The granulation process employs a fluid-bed spray granulation technique (Glatt AGT 400, Wurster insert configuration) in which a 25% w/w aqueous solution of tetramisole hydrochloride containing hydroxypropyl methylcellulose (Methocel E5 Premium LV) at 2% w/w as binder is sprayed onto the fluidized corncob substrate at a spray rate of 80 g/min, inlet air temperature 65°C, product temperature 38–42°C, and atomizing air pressure 2.5 bar. The resulting granules, with a bulk density of 0.42–0.48 g/cm³ and a Carr's Compressibility Index of ≤ 12%, exhibit free-flowing behavior in the field when poured from 25 kg multi-wall paper bags with polyethylene inner liner onto moist silage surfaces without clumping or bridging. The target application rate is 7.5 mg tetramisole hydrochloride per kilogram of animal body weight, administered as a single treatment at the commencement of the grazing season and repeated at 21-day intervals in regions with high gastrointestinal nematode challenge (pasture larval contamination exceeding 500 L3/kg dry matter of herbage as determined by modified Baermann funnel technique). The dispersible granule product is registered as a veterinary medicine or medicated feed additive depending on the jurisdiction; in Australia, it falls under the purview of the Australian Pesticides and Veterinary Medicines Authority schedule 5 for anthelmintic products, requiring compliance with APVMA MAA Standard for Anthelmintic Products (Part 2: Chemistry and Manufacture), while in New Zealand, registration by the Ministry for Primary Industries under the ACVM Act 1997 requires demonstration that the product meets the applicable standard of NZFSA Standard 53-1 for oral anthelmintic formulations with respect to dose uniformity and field stability under ambient storage conditions typical of agricultural supply chain distribution in the North Island (15–28°C, 55–80% RH). A stability-indicating analytical method using ion-pair reversed-phase HPLC with sodium dodecyl sulfate at 0.01 M in the mobile phase (pH 3.5 phosphate buffer:acetonitrile 65:35 v/v) on a 250 mm × 4.6 mm, 5 µm C18 column, detection at 215 nm, resolves the parent compound from the sulfoxide degradation product and the 2-oxo analog that forms under thermal stress, with system suitability requirements of theoretical plates ≥ 5000 for the tetramisole peak and tailing factor ≤ 1.5 applied to each batch release and ongoing stability checkpoint through the assigned 24-month shelf life.